The Danish Medicines Agency has released a dedicated Investigator’s Brochure template specifically designed for cell therapy products, providing researchers with standardized guidance aligned with European Medicines Agency advanced therapy guidelines. This template addresses the unique documentation requirements that distinguish cell-based therapies from conventional pharmaceuticals, including manufacturing consistency, cell sourcing protocols, and long-term safety monitoring.
For research institutions and sponsors, the practical benefit is clear: reduced administrative burden and faster regulatory review timelines. By offering a pre-structured framework, the template eliminates inconsistencies across applications and helps teams ensure all critical safety and quality data are properly documented from the outset. Nordic and European researchers can now access this resource to streamline their ATMP development processes, ultimately accelerating the pathway from clinical trial initiation to regulatory decision-making.
Was this article helpful?
